Enanta Pharmaceuticals Toekomstige groei

Future criteriumcontroles 1/6

De winst van Enanta Pharmaceuticals zal naar verwachting dalen met 2.7% per jaar, terwijl de jaarlijkse omzet naar verwachting zal groeien met 12.8% per jaar. De winst per aandeel zal naar verwachting groeien met 2.5% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -64.2% zijn.

Belangrijke informatie

-2.7%

Groei van de winst

2.5%

Groei van de winst per aandeel

Biotechs winstgroei	28.4%
Inkomstengroei	12.8%
Toekomstig rendement op eigen vermogen	-64.2%
Dekking van analisten	Good
Laatst bijgewerkt	09 Oct 2024

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Recent updates

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

Oct 05

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Aug 08

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Jul 24

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Jun 19

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

May 09

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Mar 05

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Feb 12

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Aug 13

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Feb 24

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Feb 08

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Nov 25

Enanta Pharmaceuticals (NASDAQ:ENTA) Has Debt But No Earnings; Should You Worry?

Jul 04

Enanta: Slow Drip

May 17

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

Feb 04

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Nov 25

Winst- en omzetgroeiprognoses

NasdaqGS:ENTA - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
Datum	Inkomsten	Inkomsten	Vrije kasstroom	Geldmiddelen uit operationele activiteiten	Gem. Aantal analisten
9/30/2027	116	-112	-276	N/A	4
9/30/2026	81	-154	-230	N/A	4
9/30/2025	74	-120	-142	-100	8
9/30/2024	71	-112	-121	-84	8
6/30/2024	72	-115	-100	-90	N/A
3/31/2024	73	-132	-113	-107	N/A
12/31/2023	74	-138	-99	-93	N/A
9/30/2023	79	-134	-112	-103	N/A
6/30/2023	81	-132	-106	-97	N/A
3/31/2023	81	-125	-102	-95	N/A
12/31/2022	82	-121	-112	-107	N/A
9/30/2022	86	-122	-87	-85	N/A
6/30/2022	89	-120	-91	-90	N/A
3/31/2022	92	-112	-91	-90	N/A
12/31/2021	93	-101	-69	-68	N/A
9/30/2021	97	-79	-71	-70	N/A
6/30/2021	97	-84	-65	-64	N/A
3/31/2021	94	-74	-40	-39	N/A
12/31/2020	102	-58	-21	-20	N/A
9/30/2020	122	-36	6	7	N/A
6/30/2020	150	2	30	31	N/A
3/31/2020	176	24	35	38	N/A
12/31/2019	188	34	48	54	N/A
9/30/2019	205	46	66	71	N/A
6/30/2019	221	65	85	91	N/A
3/31/2019	234	78	88	93	N/A
12/31/2018	238	86	52	55	N/A
9/30/2018	207	72	26	29	N/A
6/30/2018	215	81	56	58	N/A
3/31/2018	166	52	N/A	49	N/A
12/31/2017	131	34	N/A	54	N/A
9/30/2017	103	18	N/A	53	N/A
6/30/2017	40	-21	N/A	-7	N/A
3/31/2017	46	-13	N/A	-4	N/A
12/31/2016	50	-10	N/A	9	N/A
9/30/2016	88	22	N/A	36	N/A
6/30/2016	90	29	N/A	36	N/A
3/31/2016	87	33	N/A	23	N/A
12/31/2015	132	63	N/A	112	N/A
9/30/2015	161	79	N/A	77	N/A
6/30/2015	149	68	N/A	74	N/A
3/31/2015	180	116	N/A	123	N/A
12/31/2014	124	82	N/A	20	N/A
9/30/2014	48	34	N/A	20	N/A
6/30/2014	46	35	N/A	23	N/A
3/31/2014	6	-19	N/A	-18	N/A
12/31/2013	5	-19	N/A	-4	N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat ENTA de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van ENTA ( 12.8% per jaar) zal naar verwachting sneller groeien dan de markt US ( 9% per jaar).

Hoge groei-inkomsten: De omzet van ENTA ( 12.8% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat ENTA binnen 3 jaar verliesgevend zal zijn.

Enanta Pharmaceuticals Toekomstige groei

Future criteriumcontroles 1/6

Belangrijke informatie

Recente toekomstige groei-updates

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

Price target decreased by 10% to US$21.38

Consensus revenue estimates decrease by 27%, EPS upgraded

Price target decreased by 11% to US$24.38

Recent updates

Health Check: How Prudently Does Enanta Pharmaceuticals (NASDAQ:ENTA) Use Debt?

New major risk - Revenue and earnings growth

Here's What Analysts Are Forecasting For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Its Third-Quarter Results

New major risk - Revenue and earnings growth

Third quarter 2024 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2024 Results on Nov 25, 2024

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Held Back By Insufficient Growth Even After Shares Climb 26%

Senior VP & Chief Medical Officer notifies of intention to sell stock

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Using Debt In A Risky Way?

Insider notifies of intention to sell stock

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Enanta Pharmaceuticals, Inc. to Report Q3, 2024 Results on Aug 05, 2024

Second quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

Enanta Pharmaceuticals, Inc. to Report Q2, 2024 Results on May 06, 2024

Enanta Pharmaceuticals, Inc. Appoints Matthew P. Kowalsky as Chief Legal Officer

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Shares Fly 27% But Investors Aren't Buying For Growth

Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Consensus Forecasts Have Become A Little Darker Since Its Latest Report

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to US$21.38

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 06, 2024

Enanta Pharmaceuticals, Inc. Announces Retirement of Nathaniel S. Gardiner as Senior Vice President and General Counsel, Effective on or Before March 31, 2024

Independent Director recently sold US$139k worth of stock

Independent Director notifies of intention to sell stock

President recently sold US$70k worth of stock

Consensus revenue estimates decrease by 27%, EPS upgraded

New minor risk - Share price stability

Price target decreased by 11% to US$24.38

Enanta Pharmaceuticals, Inc. to Report Q1, 2024 Results on Feb 07, 2024

Price target decreased by 7.7% to US$27.89

Consensus revenue estimates increase by 13%

Time To Worry? Analysts Are Downgrading Their Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Outlook

New minor risk - Profitability

Third quarter 2023 earnings: EPS and revenues exceed analyst expectations

Enanta Pharmaceuticals, Inc. to Report Q4, 2023 Results on Nov 20, 2023

Consensus revenue estimates fall by 25%

Insufficient new directors

Enanta Pharmaceuticals, Inc. Announces Positive Data from A Phase 1 Clinical Study of Edp-323, an Oral, L-Protein Inhibitor in Development for the Treatment of Respiratory Syncytial Virus

Consensus estimates of losses per share improve by 18%

Price target decreased by 15% to US$57.40

Second quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Enanta Pharmaceuticals, Inc. to Report Q3, 2023 Results on Aug 07, 2023

Senior VP exercised options to buy US$245k worth of stock.

President notifies of intention to sell stock

We Discuss Why Enanta Pharmaceuticals, Inc.'s (NASDAQ:ENTA) CEO Compensation May Be Closely Reviewed

Consensus revenue estimates fall by 34%

Key Executive notifies of intention to sell stock

First quarter 2023 earnings: EPS and revenues exceed analyst expectations

Things Look Grim For Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) After Today's Downgrade

Enanta Pharmaceuticals, Inc. to Report Q2, 2023 Results on May 08, 2023

Enanta Pharmaceuticals, Inc., Annual General Meeting, Mar 02, 2023

President exercised options and sold US$919k worth of stock

Consensus revenue estimates fall by 10%

Downgrade: Here's How Analysts See Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Performing In The Near Term

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Enanta Pharmaceuticals, Inc. to Report Q1, 2023 Results on Feb 07, 2023

Enanta Pharmaceuticals, Inc. Initiates Sprint, a Phase 2 Clinical Trial of EDP-235, its Oral, Direct-Acting Antiviral Protease Inhibitor Specifically Designed for the Treatment of COVID-19

Is Enanta Pharmaceuticals (NASDAQ:ENTA) Weighed On By Its Debt Load?

Enanta Pharmaceuticals, Inc. Announces New Preclinical Data Supporting the Potential of EDP-235 for the Treatment of COVID-19

Enanta Pharmaceuticals, Inc. Doses First Subject in a Phase 1 Clinical Study of EDP-323, its Novel, Oral L-Protein Inhibitor in Development for the Treatment Respiratory Syncytial Virus

Enanta Pharmaceuticals, Inc. Initiates a Phase 2b Clinical Study of EDP-938 in High-Risk Adults with Respiratory Syncytial Virus

Enanta starts mid-stage trial of EDP-938 for RSV infection

Enanta Pharmaceuticals, Inc. to Report Q4, 2022 Results on Nov 21, 2022

Price target increased to US$77.00

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Enanta Pharmaceuticals, Inc. Announces Appointment of Scott T. Rottinghaus to the Position of Senior Vice President and Chief Medical Officer

Enanta Pharma FQ3 2022 Earnings Preview

Enanta Pharmaceuticals, Inc. to Report Q3, 2022 Results on Aug 08, 2022

Enanta Pharmaceuticals, Inc Announces Positive Data from A Phase 1 Clinical Study of EDP-235, Its Oral 3Cl Protease Inhibitor Designed for the Treatment of Covid-19

Enanta potential COVID drug shows safety in healthy people in early-stage trial